We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 04, 2017

Changes in HER2 Testing in Breast Cancer Following the 2013 Update to the ASCO/CAP Recommendations

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations
J. Clin. Oncol 2017 Apr 26;[EPub Ahead of Print], WM Hanna, E Slodkowska, FI Lu, H Nafisi, S Nofech-Mozes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading